Drug – bio-affecting and body treating compositions – Effervescent or pressurized fluid containing – Organic pressurized fluid
Reexamination Certificate
2005-05-10
2005-05-10
Tate, Christopher R. (Department: 1654)
Drug, bio-affecting and body treating compositions
Effervescent or pressurized fluid containing
Organic pressurized fluid
C424S046000, C424S473000, C424S499000, C528S354000
Reexamination Certificate
active
06890518
ABSTRACT:
The present invention provides active, hydrophilic polymer-modified derivatives of insulin. The insulin derivatives of the invention are, in one aspect, suitable for delivery to the lung and exhibit pharmakokinetic and/or pharmacodynamic properties that are significantly improved over native insulin.
REFERENCES:
patent: 4179337 (1979-12-01), Davis et al.
patent: 4652547 (1987-03-01), Chance et al.
patent: 4652548 (1987-03-01), Chance et al.
patent: 4654324 (1987-03-01), Chance et al.
patent: 4839341 (1989-06-01), Massey et al.
patent: 5183660 (1993-02-01), Ikeda et al.
patent: 5342940 (1994-08-01), Ono et al.
patent: 5359030 (1994-10-01), Ekwuribe
patent: 5438040 (1995-08-01), Ekwuribe
patent: 5565215 (1996-10-01), Gref et al.
patent: 5681811 (1997-10-01), Ekwuribe
patent: 5730990 (1998-03-01), Greenwald et al.
patent: 5766897 (1998-06-01), Braxton
patent: 5889153 (1999-03-01), Suzuki et al.
patent: 6309633 (2001-10-01), Ekwuribe et al.
patent: 6323311 (2001-11-01), Liu et al.
patent: 6427681 (2002-08-01), Gonda et al.
patent: 6828297 (2004-12-01), Ekwuribe et al.
patent: 20030118510 (2003-06-01), Patton et al.
patent: 0400472 (1996-04-01), None
patent: WO 9420069 (1994-09-01), None
patent: WO 9426778 (1994-11-01), None
patent: WO 9704796 (1997-02-01), None
patent: WO 982466 (1998-07-01), None
patent: WO 9921888 (1999-05-01), None
patent: WO 9932134 (1999-07-01), None
patent: WO 0006184 (2000-02-01), None
patent: WO 0040203 (2000-07-01), None
patent: WO 0078302 (2000-12-01), None
patent: WO 0168141 (2001-09-01), None
patent: WO 02092147 (2002-11-01), None
Hinds et al. Synthesis and characterization of poly(ethylene glycol)-insulin conjugates. Bioconjugate Chemistry. Mar.-Apr. 2000, 11(2): 195-201.*
Baudys et al., “Chemical Modification of Insulin to Enhance Its Physical Stability,” Proceed. Intern. Symp. Control. Rel. Bioact. Mater. (1995), vol. 22, pp. 538-539.
Baudys et al., “Design of Stable and Bioactive Insulin Conjugates,” Book of Abstracts, 212th ACS National Meeting, Orlando, FL, Aug. 25-29, 1996, Poly-012.
Baudys et al., “Design of Stable and Bioactive Insulin Conjugates,” Division of Polymer Chemistry, Inc., Polymer Preprints, vol. 37(2), Aug. 1996, pp. 117-118, Papers Presented at the Orlando, FL Meeting.
Caliceti et al., “Successful Insulin Delivery by PEG Conjugation,” Proceed. Int'l Symp. Control. Rel. Bioact. Mater. 25 (1998) Controlled Release Soc., Inc., pp. 263-264.
Ehrat et al., “Structural and Biological Properties of Polyoxyethylene-Insulin Adducts,” IUPAC, Int'l Union of Pure and Applied Chem., 28th Macromolecular Symposium, Jul. 12-16, 1982, p. 351.
Ehrat et al., “Synthesis and Spectroscopic Characterization of Insulin Derivatives Containing One or Two Poly(ethylene oxide) Chains at Specific Positions,” Biopolymers (1983). vol. 22, pp. 569-573.
Hinds et al., “Poly(Ethylene Glycol) Conjugation to Improve the Physical and Biological Properties of Insulin,” Proceed. Int'l Symp. Control. Rel. Bioact. Mater., vol. 26, (Revised Jul. 1999), Controlled Release Society, Inc., pp. 1072-1073.
Hinds et al., “Bioactive Poly(Ethylene Glycol)-Insulin Conjugates with Enhanced Stability and Reduced Immunogenicity,” Polymer Preprints (2000), vol. 4(1), pp. 987-988.
Hinds et al., “Synthesis and Characterization of Poly(ethylene glycol)-Insulin Conjugates,” Bioconjugate Chem. (2000), vol. 11, pp. 195-201.
Liu et al., “Bioactive Polyethylene Glycol Insulin Conjugates with Enhanced Stability,” Book of Abstracts, 213th ACS National Meeting, San Francisco, Apr. 13-17, 1997, Poly-223.
Liu et al., “Glucose-Induced Release of Glycosylpoly(ethylene glycol) Insulin Bound to a Soluble Conjugate of Concanavalin A,” Bioconjugate Chem. 1997, vol. 8, pp. 664-672.
Neubauer et al., “Influence of Polyethylene Glycol Insulin on Lipid Tissues of Experimental Animals,” Diabetes, vol. 32, Oct. 1983, pp. 953-958.
Uchio et al., “Site-Specific Insulin Conjugates with Enhanced Stability and Extended Action Profile,” Advanced Drug Delivery Reviews (1999), vol. 35, pp. 289-306.
Veronese et al., “PEG Peptide and Protein Drug Delivery: A Procedure to Identify the Peglation Site,” Proc. Int'l Symp. Control. Release Bioact. Mater. (1999), vol. 26, pp. 106-107.
Zia et al., “Comparison of Nasal Insulin Powders Prepared by Supercritical Fluid and Freeze-Drying Techniques,” Particulate Sci. Technol. (1997), vol. 15(3-4), pp. 273-301.
Bueche Blaine
Harris J. Milton
Kuo Mei-Chang
Leach Chester
Patton John S.
Audet Maury
Evans Susan T.
Nektar Therapeutics
LandOfFree
Compositions of chemically modified insulin does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions of chemically modified insulin, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions of chemically modified insulin will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3459665